GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Float Percentage Of Total Shares Outstanding

Medivir AB (Medivir AB) Float Percentage Of Total Shares Outstanding : 0.00% (As of Apr. 30, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Medivir AB's float shares is 0.00 Mil. Medivir AB's total shares outstanding is 55.83 Mil. Medivir AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Medivir AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Medivir AB's Institutional Ownership is 17.70%.

Medivir AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Medivir AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/55.83
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB (Medivir AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
OSTO:SYNACT OSTO:ACE XSAT:HAMLET B XSAT:CURAS OSTO:IVACC OSTO:MAGLE OSTO:CLBIO OSTO:NICA OSTO:IMMU OSTO:SANION OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
MVIR:Sweden MVR0:Germany
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Website
https://www.medivir.com
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.